<b>Background:</b> Germline breast cancer susceptibility gene 1/2 (<i>BRCA1/2</i>) variants guide breast cancer treatment, but their clinical relevance in metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) remains unclear. This evidence concerns the gene BRCA1 and breast carcinoma.